News

Mesoblast Restricted Buyers: Firm investigated by the regulation agency Portnoy – Yahoo Finance

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Investors can contact the law firm for free to learn more about recovering their losses"data-reactid =" 12 "> Investors can contact the law firm free of charge to learn more about how to recover their losses

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "LOS ANGELES, August 19, 2020 (GLOBE NEWSWIRE) – The Portnoy Law Office advises Mesoblast Limited ("Mesoblast" or the "Company") (Nasdaq: MESO) investors that the company has initiated an investigation into possible securities fraud and may commence a class action lawsuit on behalf of investors. The investigation focuses on violations of securities laws.
"data-reactid =" 13 "> LOS ANGELES, August 19, 2020 (GLOBE NEWSWIRE) – The law firm Portnoy advises investors in Mesoblast Limited (" Mesoblast "or" Company ") (Nasdaq: MESO) has launched an investigation into possible securities fraud and may file class action lawsuits on behalf of investors.The investigation focuses on violations of securities laws.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Investors are asked to contact their lawyer Lesley F. PortnoyBy phone at 310-692-8883 or E-mail: lesley@portnoylaw.com to discuss your legal rights, or Click here to join the case over www.portnoylaw.com. Portnoy law firm can provide a free case assessment and discuss investor options for pursuing claims for redress for their losses. "Data-reactid =" 14 "> Investors are asked to call lawyer Lesley F. Portnoy on 310-692-8883 or send an email to: lesley@portnoylaw.com to find out their legal rights or click here to join the loss case on www.portnoylaw.com.

The investigation focuses on whether the company has made misleading and / or false information and / or failed to disclose information that is relevant to investors. On August 11, 2020, the FDA released briefing materials for the Oncological Medicines Advisory Committee meeting on August 13, 2020. The meeting was intended to promote the marketing application of mesoblast for ryoncil (Remestemcel-L) for the treatment of steroid-refractory acute graft-versus-host disease Discuss in pediatric patients. According to the FDA briefing documents, it was "unclear" whether these study results are "relevant" to the proposed indication. On August 11th, shares of Mesoblast fell nearly 35% on the news.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Please visit our website To review more information and submit your transaction information. "data-reactid =" 20 "> Please visit our website to review more information and submit your transaction information.

Portnoy law firm represents investors in pursuing claims arising from corporate infringements. The company's founding partner has confiscated over $ 5.5 billion for aggrieved investors. Lawyer advertising. Previous results do not guarantee similar results.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Lesley F. Portnoy, Esq.
Approved CA and NY bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com "data-reactid =" 22 "> Lesley F. Portnoy, Esq.
Approved CA and NY bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Lawyer advertising

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "
"data-reactid =" 24 ">

0 Comments
Share

labsurlab

Reply your comment

Your email address will not be published. Required fields are marked*